A carregar...
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
Risankizumab, a humanized monoclonal antibody that targets interleukin‐23 p19 subunit, was developed for the treatment of psoriasis. This work characterizes risankizumab pharmacokinetics in Japanese and Chinese healthy subjects compared with white healthy subjects and in Japanese patients with moder...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6852105/ https://ncbi.nlm.nih.gov/pubmed/31257614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1473 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|